FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer


In Partnership With:

Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Ursula A. Matulonis, MD, chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School. Dr Matulonis joined us to talk about the FDA approval of mirvetuximab soravtansine-gynx (Elahere) in patients with folate receptor α (Frα)–positive, platinum-resistant ovarian cancer.

On November 14, 2022, the FDA gave accelerated approval to mirvetuximab soravtansine in adults with Frα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received between 1 and 3 prior systemic treatments. The approval was supported by findings from the phase 3 SORAYA trial (NCT04296890), which showed an objective response rate of 31.7% and a duration of response of 6.9 months in those who received the agent.

In our exclusive interview, Dr Matulonis discussed the significance of this approval, key efficacy and safety data from SORAYA, and how further research, including the ongoing phase 3 MIRASOL trial (NCT04209855), can continue the momentum behind finding effective treatments for patients with ovarian cancer.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Abdulrahman Sinno, MD
Amin Nassar, MD
Haeseong Park, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Jennifer Brown, MD, PhD
Rebecca L. Porter, MD, PhD
Wenxin (Vincent) Xu, MD,